Table 2.

Lotinib/gefitinib response and EGFR mutations of 29 lung cancer patients.

Cases	Cancer subtype	Drug responses	Tumor stage	EGFR mutation				ERBB2 amplification
1	LUAD	R	IV	T790M			L858R
2	LUAD	R	III	T790M			L858R
3	LUAD	R	IV				L858R
4	LUAD	R	–	T790M			L858R
5	LUAD	R	IV	T790M			L858R
6	LUAD	R	III				L858R	yes
7	LUAD	R	IV	T790M	19 exon del	Amplification
8	LUAD	R	–		19 exon del	Amplification
9	LUAD	R	IV	T790M	19 exon del	Amplification
10	SCLC	R	IV		19 exon del	Amplification
11	LUAD	R	IV	T790M	19 exon del	Amplification
12	LUAD	R	IV	T790M	19 exon del	Amplification
13	LUAD	R	IV	T790M	19 exon del	Amplification
14	LUSC	R	IV	T790M	19 exon del	Amplification
15	LUAD	R	III		19 exon del			yes
16	LUAD	R	IV	T790M	19 exon del
17	LUAD	R	–		19 exon del
18	LUAD	R	–		19 exon del
19	NSCLC	R	IV		19 exon del
20	LASC	R	IV			Amplification
21	SCLC	R	IV			Amplification
22	LUAD	R	–	T790M		Amplification	L858R
23	LUAD	S	IV	T790M	19 exon del
24	NSCLC	S	–	T790M	19 exon del
25	LUAD	S	IV	T790M	19 exon del
26	LUAD	S	IV		19 exon del
27	LUAD	S	–		19 exon del
28	LUAD	S	IV	T790M	19 exon del	Amplification
29	LUAD	S	I				L858R

LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, LASC lung adenosquamous cell carcinoma, SCLC small cell lung cancer.